From Norway to Novartis: Cyclosporin from Tolypocladium inflatum in an open access bioprospecting regime

Biodiversity and Conservation

Volumn 9, Issue 11, 2000, Pages 1521-1541

  Svarstad, Hanne ^a   Bugge, Hans Chr ^a   Dhillion, Shivcharn S ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

Author keywords

Bioprospecting; Convention on Biological Diversity; Cyclosporin; Genetic resources; Hyphomycetes; Novartis; Tolypocladium inflatum

Indexed keywords

EID: 0033662566     PISSN: 09603115     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008990919682     Document Type: Article

References (78)

1. Healthcare products top Novartis' growth agenda
2. Novartis puts in a strong first year performance
3. Bioprospecting - Temperate fungi tapped for drugs
4. Mikrosvamper i svenska barskogsjordar
5. Natural product drug discovery and development - New perspectives on international collaboration
6. The panorama of cyclosporin research
7. Biopiracy's latest disguises
8. Notes on Tolypocladium and related genera
9. The distribution of fungi in some alpine soils
10. The discovery and development of cyclosporine (Sandimmune)
11. Biological effects of cyclosporin A: A new antilymphocytic agent
12. Effects of the new anti-lymphocytic peptide cyclosporin A in animals
13. Valuing biodiversity: The scope and limitations of economic analysis
14. Using fungi from a node of biodiversity: Conservation and property rights in Oaxacan forests
15. Cost of innovation in the pharmaceutical industry
16. Roche deCODEs Icelandic population in $ 200 million deal
17. Proposal to reject Pachybasium niveum Rostr. in order to retain the name Tolypocladium inflatum W. Gams for the fungus that produces cyclosporin
18. Prospecting for nature's chemical fiches
19. Chemical prospecting: A proposal for action
20. Bioprospecting or biopiracy?
21. Opplysninger om Novartis og Sandimmun Neoral
22. Fungi and international biodiversity initiatives
23. Microbial diversity and ecosystem processes. Section 6, biodiversity and ecosystem functioning: Ecosystem analyses
24. An African perspective
25. Conclusion
26. Legal questions concerning the implementation of Article 15 paragraph five of the Convention on Biological Diversity
27. The 'Facilitator': Proposing a new mechanism to strengthen the equitable and sustainable use of biodiversity
28. Contracts for biodiversity prospecting
29. Natural products and the pharmaceutical industry
30. Bioprospecting and conservation in Costa Rica
31. Biological diversity, chemical diversity, and the search for new pharmaceuticals
32. Managing access to genetic resources
33. Fra hoyfjells-sopp til menneskegener
34. Monetizing the pharmacological benefits of plants
35. The cyclosporins
36. Technological change and regulation of access to genetic resources
37. A new lease on life
38. A landmark year for biodiversity or bio-piracy?
39. Biodiversity Prospecting
40. Valuing biodiversity for use in pharmaceutical research
41. The history of cyclosporin A (Samdimmune) revisited: Another point of view
42. National sovereignty and genetic resources
43. Biologisk mangfold: Ressurser i Sor og interesser i Nord
44. Reciprocity, biopiracy, heroes, villains and victims
45. Biopiracy or Green Petroleum? Expectations and Best Practice in Bioprospecting
46. Cyclosporins: Immunosuppressive drugs with anti-HIV-1 activity
47. The Discovery and Development of Cyclosporin
48. Fungal biodiversity: A British mycological society symposium
49. Fungal biodiversity
50. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine Sandimmune versus the microemulsion neoral in heart transplant recipients
51. Soppen fra Hardangervidda